BIRC5 and malignant colon neoplasm: In mice colon cancer model, a combination therapy involving stattic was found to significantly enhance the antitumor T cell response, improve long-term survival, and reduce the immunosuppressive TME, compared to survivin mRNA monotherapy (64).